SAN DIEGO, Calif., Dec. 10, 2015 /PRNewswire/ -- Sequenom, Inc.
(NASDAQ: SQNM), a life sciences company committed to enabling
healthier lives through the development of innovative products and
services, today announced that its Board of Directors has appointed
current Interim President and Chief Executive Officer Dirk van den Boom, Ph.D. as President and Chief
Executive Officer, effective immediately. Dr. van den Boom will also retain his seat on
Sequenom's Board of Directors.
"The Board's unanimous decision reflects our strong confidence
in Dirk's ability to execute on our strategic plan and to restore
Sequenom's growth," said Dr. Kenneth
Buechler, Chairman of Sequenom's Board of
Directors. "Dirk is a proven leader with a long history at
Sequenom, deep scientific knowledge of our products, experience
developing and implementing Sequenom's business strategy, and the
demonstrated ability to bring our people together to accomplish
goals. In the space of only 11 weeks since he was appointed
Interim President and Chief Executive Officer, he has established a
clear path forward for Sequenom, focusing on entering a new market
channel, driving the growth of our newest product,
MaterniT® GENOME, and bringing new efficiencies to
Sequenom's operations. The company is well positioned to
execute on these and other opportunities, and the Board is
confident that there is no better leader than Dirk to realize
Sequenom's potential."
Dr. van den Boom also commented,
"I am honored by the opportunity to lead Sequenom into this next
chapter. We remain focused on bringing the best products to
market while aggressively positioning the company for success and
expanding our leadership in the field."
Dr. van den Boom joined Sequenom
in 1998 and has served in various management roles within
Sequenom's R&D department. More recently, he has served as
the company's Chief Scientific and Strategy Officer, and in
September 2015 was appointed Interim
President and Chief Executive Officer. Dr. van den Boom received his Ph.D. in
biochemistry/molecular biology from the University of Hamburg where he focused on various aspects of
nucleic acid analysis with mass spectrometry. He has co-authored
more than 50 scientific articles and is an inventor on 48
patents/patent applications.
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is
committed to enabling healthier lives through the development of
innovative products and services. The Company serves patients
and physicians by providing early patient management
information. To learn how Sequenom is interpreting the genome
to improve your life, visit www.sequenom.com.
About Sequenom Laboratories
Sequenom Laboratories, a
CAP-accredited and CLIA-certified molecular diagnostics laboratory,
has developed a broad range of laboratory tests, with a focus
principally on prenatal care. Branded under the names
HerediT®, HerediT® UNIVERSAL,
MaterniT® GENOME, MaterniT21® PLUS,
NextView®, SensiGene® and VisibiliT™, these molecular genetic
laboratory-developed tests provide early patient management
information for obstetricians, geneticists, and maternal fetal
medicine specialists. Sequenom Laboratories is changing the
landscape in genetic diagnostics using proprietary cutting edge
technologies. Visit www.laboratories.sequenom.com and follow
@SequenomLabs.
SEQUENOM®, HerediT®,
MaterniT® GENOME, MaterniT21® PLUS,
NextView®, SensiGene®, VisibiliT™
and Sequenom Laboratories™ are trademarks of Sequenom,
Inc. All other trademarks and service marks are the property of
their respective owners.
Forward-Looking Statements
Statements contained in
this press release regarding matters that are not historical facts
are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 including statements
regarding the development of innovative products and services, the
ability to execute on our strategic plan and restore Sequenom's
growth, the ability to drive the growth of MaterniT®
GENOME, the ability to bring products to market, the ability to
expand Sequenom's leadership in the field and the ability to bring
new efficiencies to Sequenom's operations. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Risks are described more fully in the Company's
filings with the Securities and Exchange Commission, including
without limitation the Company's most recent Quarterly Report on
Form 10-Q and other documents subsequently filed with or furnished
to the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. The Company undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
![SEQUENOM logo. SEQUENOM logo.](http://photos.prnewswire.com/prnvar/20040415/SQNMLOGO)
Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sequenom-announces-appointment-of-dirk-van-den-boom-as-president-and-chief-executive-officer-300191645.html
SOURCE Sequenom, Inc.